Eli Lilly and Company Q2 2026 Earnings Call Summary

Eli Lilly and Company Q2 2026 Earnings Call Summary Moby Intelligence Thu, August 6, 2026 at 4:13 AM GMT+2 3 min read NVDA LLY Eli Lilly and Company Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Revenue growth of 48% was primarily catalyzed by the massive scale-up of Zepbound and Mounjaro, which contributed $6. 3 billion in incremental growth compared to the prior year. Management attributed the 121% growth in Oncology, Immunology, and Neuroscience to successful portfolio diversification and the rapid uptake of new medicines like Inluriyo and Kisunla.

The U. S. Foundayo launch is transitioning from a physician education and access-securing phase to a broad direct-to-consumer marketing phase to capture pent-up demand.

Gross margin expansion to 86. 3% was driven by a favorable product mix and manufacturing efficiencies, despite significant investments in promotional activities for new launches. Strategic business development accelerated with acquisitions of Curevo, LimmaTech, and Vaccine Company, marking a deliberate entry into the infectious disease prevention market.

The acquisition of AtaiBeckley signals a strategic pivot toward rapid-acting neuroplastogens to address high unmet needs in treatment-resistant depression. International market leadership in incretins was strengthened to approximately 55% share, with management focusing on market expansion rather than just share gains in mature regions. Outlook and Strategic Initiatives Full-year revenue guidance was raised to $85 billion–$87 billion, reflecting strong first-half performance and the anticipated impact of expanded obesity access.

The Medicare GLP-1 Bridge program is expected to unlock access for 20 million eligible Americans, potentially increasing the obesity treatment population by 35%. Management expects a global rollout of Foundayo in all major international markets by 2027, following regulatory reviews currently underway in over 40 countries. Retatrutide global registrations for obesity and related comorbidities are planned for Q1 2027, utilizing the BLA pathway to reflect its biologic nature.

Future growth assumptions include the readout of EMBER-4 in the adjuvant breast cancer setting and the potential for orforglipron to become a foundational daily oral treatment for type 2 diabetes. Operational and Risk Factors Q2 results included $3. 03 per share in acquired IPR&D charges, reflecting the high pace of recent business development and pipeline expansion.

U. S. price declines of 9% (excluding rebate adjustments) for Zepbound and Mounjaro reflect the strategic shift toward broader access and the impact of self-pay segments.

Manufacturing capacity remains a focus, with the opening of a new genetic medicine facility in Indiana and the first commercial batch produced in Ireland to support global demand. Management noted that while early Foundayo uptake in the UAE is encouraging, international growth will increasingly depend on securing government reimbursement for obesity. Story Continues Q&A Insights Foundayo U.

S. launch trajectory and inflection points One stock. Nvidia-level potential.

30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management reported a significant inflection in late July, with volume nearly doubling in a month as commercial access and the Medicare Bridge program went live. Approximately 1 out of 4 new patient starts are now on Foundayo, with 36,000 active prescribers compared to 8,000 in the previous quarter. Retatrutide regulatory pathway and BLA classification Lilly is pursuing the BLA pathway based on the molecule's amino acid count and biologic properties, despite ongoing litigation regarding FDA classifications.

The clinical data package is complete, but the Q1 2027 filing timeline accounts for additional CMC (Chemistry, Manufacturing, and Controls) data collection. Impact of generic semaglutide in international markets Management observed continued growth for Mounjaro in India and Brazil despite generic entries, citing the clinical superiority of tirzepatide as a primary defense. Early observations suggest generic competitors are facing significant supply constraints, similar to the challenges faced by branded manufacturers.

Sustainability of Zepbound net pricing and medical exceptions Management expects net prices to trend downward as medical exceptions are replaced by broad formulary access, such as the new CVS agreement starting in Q4. The company intends to offset lower per-unit pricing with massive volume growth as more Americans gain insurance coverage for obesity treatments.